文献速递心境障碍儿童青少年精神

孕期抗抑郁药使用与子代智力障碍的关联

Association of Antidepressant Medication Use During Pregnancy With Intellectual Disability in Offspring.
PubMed 文献 · JAMA Psychiatry · 2017-01-01

未调整分析显示ID风险增加,但调整混杂因素后,全样本RR为1.33(95%CI 0.90-1.98),抑郁母亲亚样本RR为1.64(95%CI 0.95-2.83),均无统计学显著性。结论认为未发现孕期抗抑郁药使用与ID的独立关联,关联可能归因于父母年龄和母亲精神疾病等因素。

要点

  • 调整混杂后,孕期抗抑郁药暴露与子代ID风险无显著关联(RR 1.33,95%CI 0.90-1.98)。
  • 在抑郁母亲亚样本中,关联亦不显著(RR 1.64,95%CI 0.95-2.83)。
  • SSRI、非SSRI抗抑郁药及其他精神药物分析结果与全样本一致。

核心结论

  • 调整混杂因素后,本研究未发现孕期母亲抗抑郁药使用与子代智力障碍存在关联。
  • 观察到的未调整关联可能归因于父母年龄和母亲精神疾病等其他因素。

研究设计与样本

  • 暴露为孕期母亲使用任何抗抑郁药、SSRI、非SSRI抗抑郁药或其他非抗抑郁精神药物。
  • 主要结局为子代智力障碍诊断,估计相对风险(RR)及95%CI并调整潜在混杂因素。

主要发现

  • 调整混杂后,全样本中抗抑郁药暴露的ID相对风险为1.33(95%CI 0.90-1.98)。
  • 抑郁母亲亚样本中,抗抑郁药暴露的ID相对风险为1.64(95%CI 0.95-2.83)。
  • SSRI、非SSRI抗抑郁药及非抗抑郁精神药物的分析结果与全样本结果无偏离。

关键数值与推荐

  • 全样本调整后RR=1.33(95%CI 0.90-1.98),无统计学显著性。
  • 抑郁母亲亚样本调整后RR=1.64(95%CI 0.95-2.83),无统计学显著性。

临床怎么用

  • 临床咨询时可告知:调整混杂后未发现孕期抗抑郁药使用与子代智力障碍的显著关联。
  • 应综合评估母亲精神疾病本身及父母年龄等因素对子代结局的潜在影响。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Maternal antidepressant medication use during pregnancy has previously been associated with adverse outcomes in offspring, but to our knowledge, the association with intellectual disability (ID) has not been investigated. OBJECTIVES: To examine the association of maternal antidepressant medication use during pregnancy with ID in offspring and investigate the importance of parental mental illness for such an association. DESIGN, SETTING, AND PARTICIPANTS: A population-based cohort study of 179 007 children born from January 1, 2006, through December 31, 2007, with complete parental information from national registers who were followed up from birth throughout 2014. MAIN OUTCOMES AND MEASURES: We estimated relative risks (RRs) and 95% CIs of ID in children exposed during pregnancy to any antidepressant medication or specifically to selective serotonin reuptake inhibitor (SSRI) antidepressants, all other non-SSRI antidepressants, or other nonantidepressant psychotropic medications. Analyses were adjusted for potential confounders. In addition to full population analyses, we used a subsample to compare mothers who used antidepressants during pregnancy with mothers who had at least one diagnosis of depression or anxiety before childbirth but did not use antidepressants during pregnancy. RESULTS: Of the 179 007 children included in the study (mean [SD] age at end of follow-up, 7.9 [0.6] years; 92 133 [51.5%] male and 86 874 [48.5%] female), ID was diagnosed in 37 children (0.9%) exposed to antidepressants and in 819 children (0.5%) unexposed to antidepressants. With adjustment for potential confounders, the RR of ID after antidepressant exposure was estimated at 1.33 (95% CI, 0.90-1.98) in the full population sample and 1.64 (95% CI, 0.95-2.83) in the subsample of women with depression. Results from analyses of SSRI antidepressants, non-SSRI antidepressants, and nonantidepressant psychotropic medications and analyses in the clinically relevant subsample did not deviate from the full-sample results. CONCLUSIONS AND RELEVANCE: The unadjusted RR of ID was increased in offspring born to mothers treated with antidepressants during pregnancy. After adjustment for confounding factors, however, the current study did not find evidence of an association between ID and maternal antidepressant medication use during pregnancy. Instead, the association may be attributable to a mechanism integral to other factors, such as parental age and mother's psychiatric disorder.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Viktorin A, Uher R, Kolevzon A, et al. Association of Antidepressant Medication Use During Pregnancy With Intellectual Disability in Offspring. JAMA Psychiatry. 2017. PMID: 28700807. doi:10.1001/jamapsychiatry.2017.1727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。